STOCK TITAN

Boston Scien Cp - BSX STOCK NEWS

Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.

Boston Scientific Corporation (BSX) delivers innovative medical solutions through advanced devices for cardiovascular care, neuromodulation, and minimally invasive procedures. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product innovations, and strategic initiatives shaping the future of patient care.

Access official press releases covering clinical trial results, FDA clearances, and financial performance alongside analysis of emerging trends in interventional therapies. Our curated collection includes updates on electrophysiology advancements, urological device developments, and global healthcare partnerships.

Key updates feature Boston Scientific's leadership in catheter-based technologies, progress in chronic pain management solutions, and expansions in diagnostic imaging capabilities. Stay informed about acquisitions, research collaborations, and quality improvement initiatives that reinforce the company's market position.

Bookmark this page for direct access to verified information about BSX's contributions to interventional cardiology and operational developments. Regularly updated to serve as your primary resource for understanding Boston Scientific's impact on modern healthcare delivery.

Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) announced FDA approval for TheraSphere™ Y-90 Glass Microspheres to treat hepatocellular carcinoma (HCC). This approval enhances access to a therapy previously limited under humanitarian device exemptions. HCC is a prevalent cancer, with an estimated 32,000 new U.S. cases in 2021. Results from the LEGACY study demonstrated high response rates and overall survival, with 100% patient response seen after two treatments. The outpatient procedure reduces hospital burdens and aligns with recent NICE recommendations, indicating improved patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) has signed a definitive agreement to acquire Lumenis LTD.'s global surgical business for $1.07 billion. The deal, expected to close in the second half of 2021, includes Lumenis's innovations in energy-based medical solutions, specifically in urology and otolaryngology. With anticipated 2021 net sales of $200 million, the acquisition aims to enhance Boston Scientific's stone management offerings and expand its market presence in Europe and Asia. The impact on earnings per share is projected to be immaterial in 2021 but accretive starting in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
-
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will participate in two investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, featuring CFO Dan Brennan and VP Susie Lisa, and the Cowen 41st Annual Health Care Conference on March 1, 2021, with SVP Meghan Scanlon and VP Susie Lisa. Each session will include a 30-minute Q&A segment. Live webcasts and replays will be available via the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Rhea-AI Summary

Boston Scientific reported Q4 2020 net sales of $2.708 billion, showing a decline of (6.8)% compared to Q4 2019. GAAP net income available to common stockholders was $138 million or $0.10 EPS, significantly down from $3.996 billion or $2.83 EPS a year prior. For the full year 2020, sales totaled $9.913 billion, down (7.7)%. The transition to a consignment model for WATCHMAN customers impacted results negatively. The company received multiple FDA approvals and is planning growth for 2021 with projected revenue increases of 13% to 19%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
Rhea-AI Summary

Boston Scientific Corporation has received FDA approval for the fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System, enhancing treatment options for over 10 million people globally with Parkinson's disease. This system includes Bluetooth-enabled, rechargeable, and non-rechargeable implantable pulse generators that work with Cartesia™ Directional Leads for optimal symptom relief. The company plans a controlled U.S. launch following its European debut in September 2020, potentially improving patient access and outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
-
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced its agreement to acquire Preventice Solutions for up to $1.225 billion, including $925 million upfront and additional milestone payments. This strategic acquisition aims to enhance Boston Scientific's position in the growing ambulatory cardiac monitoring market, valued at nearly $2 billion. Preventice reported $158 million in net sales for 2020, showing a 30% growth. The deal, expected to close by mid-2021, is projected to be accretive by at least one cent per share in 2022. The acquisition aligns with Boston Scientific's focus on innovative cardiac health solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced the limited release of the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) systems. This portfolio includes four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs) that promise personalized pain relief through Fast Acting Sub-perception Therapy (FAST™). Currently, chronic pain affects over 50 million Americans, and traditional therapies can take longer to act. The FDA approved these systems in December 2020, indicating their use in managing chronic intractable pain, including conditions like Complex Regional Pain Syndrome.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) reported preliminary fourth-quarter 2020 net sales of approximately $2.71 billion, a decline of about 6.8% year-over-year. For the full year, net sales totaled approximately $9.91 billion, down 7.7%. Key challenges included a significant drop in WATCHMAN™ device sales due to inventory model changes, impacting organic growth by 8% in Q4. Some segments like Peripheral Interventions saw growth (4.8% organic), while Cardiovascular reported a significant decline of 12%. The company expects to discuss these results in detail during upcoming earnings calls.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary

Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. EST. CEO Mike Mahoney will present, followed by a Q&A session with other executives, including Dan Brennan and Dr. Ian Meredith. On February 3, 2021, the company will hold a webcast at 8:00 a.m. EST to discuss its fourth-quarter financial results, announcing earnings prior to the call. The events will be available for live streaming and replay on their investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences
Rhea-AI Summary

Boston Scientific (NYSE: BSX) announced the sale of its BTG Specialty Pharmaceuticals business to SERB for $800 million in cash. The divestiture aims to enhance the BTG business's potential within specialty pharmaceuticals, particularly in life-saving antidotes. The BTG Specialty Pharmaceuticals is projected to generate $210 million in revenue for 2020. This sale follows the acquisition of BTG for approximately $3.7 billion, resulting in over $1 billion in net proceeds from divested businesses. The transaction is expected to close in H1 2021, pending regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Stock Data

140.69B
1.47B
0.2%
93.36%
0.87%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH